We show that loss of KEAP1 reduces sensitivity of RET fusion-positive PTC cells to the receptor tyrosine kinase inhibitor selpercatinib, a key therapeutic agent for RET-driven thyroid cancers. This evidence concerns the gene KEAP1 and thyroid cancer.